An integrated model of cellular states, tissue plasticity and genetics provides comprehensive insights for brain cancer immunotherapy
http://bit.ly/2MeTVir
Image credit: Neftel et al. 2019
Mike Driver
Acquired Stardust
d e v o n

No title available
I'd rather be in outer space 🛸
Keni
YOU ARE THE REASON
Game of Thrones Daily
art blog(derogatory)

祝日 / Permanent Vacation

⁂

★
Today's Document
Alisa U Zemlji Chuda
Cosimo Galluzzi

❣ Chile in a Photography ❣
he wasn't even looking at me and he found me
2025 on Tumblr: Trends That Defined the Year

ellievsbear
Peter Solarz

seen from Malaysia

seen from United Kingdom

seen from Malaysia

seen from United States
seen from United States
seen from Algeria
seen from United Kingdom

seen from Romania
seen from Germany
seen from Germany

seen from United Kingdom

seen from Malaysia
seen from Germany

seen from Malaysia

seen from Türkiye

seen from Malaysia

seen from Malaysia
seen from Australia

seen from Malaysia
seen from Germany
@stojdllab
An integrated model of cellular states, tissue plasticity and genetics provides comprehensive insights for brain cancer immunotherapy
http://bit.ly/2MeTVir
Image credit: Neftel et al. 2019
After PD-1 blockade, the T cells that expand don't seem to be pre-existing tumor-infiltrating T lymphocytes but instead T cells with novel reactivities that weren't previously present in the tumour
https://go.nature.com/2BdZw2p
Image credit: Yost et al. 2019
Monitoring local vs. peripheral changes in cellular immunomes during cancer immunotherapy
Interesting study from Frontiers in Immunology & Duke University getting their biomarker immune analysis ready to go for an oncolytic virus trial for recurrent glioblastoma.
http://bit.ly/35AXrLI
T-Scan: a genome-wide, high-throughput method for the systematic discovery of T cell epitopes
http://bit.ly/2VEVyZU
Image credit: Kula et al. 2019
The compartmental distribution of PD-L1 might dictate whether we should block it, knock it down or inhibit it during cancer immunotherapy
http://bit.ly/2ONuTZM Image credit: Wu et al. 2019
Physically crosslinked injectable hydrogels for the long-term delivery of oncolytic viruses for cancer therapy
https://rsc.li/2Mpfmfz
Image credit: Le et al. 2019
Fascinating paper describes how blocking tumour IFNg signalling can actually stimulate exhausted T cells to produce more IFNg & reject tumours with favorable antigenicity profiles
http://bit.ly/2AVuTia
Image: Benci et al. 2019
Targeting cancer stem cells and their supportive niche using oncolytic virus immunotherapy
http://bit.ly/2p3HA7A
Image credit: Crupi et al. 2019
Cool new technology: empty-loadable tetramers that convert into antigen-specific tetramers by a single-step peptide addition & can identify neoantigen -specific T cells for cancer immunotherapy
http://bit.ly/2VmAkji Image: Saini et al. 2019
Interesting review on rationally combining immunotherapy with synergistic radiotherapy to mobilise anti-cancer immunity
http://bit.ly/30UNpBI Image credit: Herrera et al. 2019
Chemo-radiotherapy can upregulate PD-L1 expression in tumour samples, providing a clinical rationale for subsequent immune checkpoint inhibition
https://go.nature.com/33A11oG
Image credit: Yoneda et al. 2019
Gene panels designed to estimate tumour mutation burden should move away from 'correlation' to focus on 'accuracy' to avoid overestimation
http://bit.ly/31Dd16H
Image credit: Wu et al. 2019
Alternative mRNA splicing alters the proteomic diversity of many cancers and may offer a broader target space for cancer immunotherapy
https://go.nature.com/2Kw1LDC
Image credit: Frankiw et al. 2019
Immune conversion of the tumour microenvironment by oncolytic viruses
http://bit.ly/2KJahxU
Image credit: Marchini et al. 2019
Our newest publication is out!
Co-delivering mRNA wrapped in a new lipopolyplex formulation induces a strong anti-tumour immune response upon intravenous administration
http://bit.ly/2KGrSGM Image credit: Guevara et al. 2019
Mutation-derived neoantigens for cancer immunotherapy
http://bit.ly/2YFmzk9
Image credit: Castle et al. 2019
Diverse cancer immunotherapies can effectively treat syngeneic brainstem tumours in the absence of overt toxicity
http://bit.ly/2yHh5q8
Image credit: Schuelke et al. 2019